11.2024
Society for Immunotherapy of Cancer (SITC) Annual Meeting (2024)
Phase 2 study of pembrolizumab (Pemb) plus plinabulin (Plin) and docetaxel (Doc) for patients with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: updated efficacy and safety results on immune re-sensitization